Cannabis Research Paper

is under the editorial leadership of Daniele Piomelli, Ph D, the Louise Turner Arnold Chair in Neurosciences and Professor of Anatomy and Neurobiology, Pharmacology, and Biological Chemistry at University of California, Irvine.

Audience: Pharmacologists and psychopharmacologists, toxicologists, biochemists, neurologists, psychiatrists, physicians, and other healthcare practitioners, addiction specialists, and regulators and policymakers, among others The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Dried flower was the most commonly used product and generally associated with greater symptom relief than other types of products.

Across product characteristics, only higher THC levels were independently associated with greater symptom relief and prevalence of positive and negative side effects.

Our final sample includes 19,910 sessions and 3,341 patients who recorded at least one product characteristic in the Releaf App between 06/06/2016 and 03/05/2018.

Because the entry of product characteristics is voluntary, the sample sizes used in our analyses vary depending on which product characteristics are included.From that time until the patient closes the session, they can enter multiple symptom severity levels as frequently as desired.For the current analyses, we include in our sample only patients entering starting symptoms greater than 0 and recording at least one symptom level within 90 minutes of starting the session; we use the last symptom level recorded within that timeframe as the ending symptom level.What little clinical research does exist is mostly limited to randomized controlled trials (RCTs) using synthetic cannabinoids or low quality and potency cannabis obtained from the federal government that is unrepresentative of the cannabis products used by millions of people every day.Contributing to further confusion are historically contradictory messages coming from the scientific community on the true risks and benefits of cannabis consumption.In actuality, few large-scale investigations to date have measured the relative effects of THC and CBD consumption in real-time under naturalistic conditions among people diagnosed with schizophrenia or any other user group.This is the first study to measure how fundamental characteristics of cannabis products consumed in vivo affect immediate symptom relief and experienced side effects.MAPS is working to demonstrate the safety and efficacy of smoked botanical marijuana as a prescription medicine for specific medical uses to the satisfaction of the U. NIDA's previous monopoly on the supply of marijuana for research and the DEA's prior refusal to allow researchers to grow their own has restricted medical marijuana research for decades. MAPS worked for over 22 years to obtain marijuana for medical marijuana drug development research, and the approval is a historic shift in federal policy. Our efforts to initiate medical marijuana research have been hindered by the National Institute on Drug Abuse (NIDA) and the Drug Enforcement Administration (DEA) since our founding in 1986.Releaf App users voluntarily download the application and enter information on the product they intend to consume, including type of product (whole natural dried flower, concentrate, edible, tincture, and topical); when applicable, combustion method (joint, dry or water pipe, and vape); plant subspecies (C. sativa, or hybrid); and THC and CBD potency levels (percentage of total weight).Testing of the potencies of both cannabinoids is almost universally required under U. medical marijuana laws and generally reported on product labels.


Comments Cannabis Research Paper

The Latest from ©